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Abstract 
Conotoxin GeXIVA inhibits the α9α10 nicotinic acetylcholine receptor (nAChR) and is analgesic in animal 
models of pain. α-Conotoxins have four cysteines that can have three possible disulfide connectivities: 
globular (CysI-CysIII and CysII-CysIV), ribbon (CysI-CysIV and CysII-CysIII), or bead (CysI-CysII and 
CysIII-CysIV). Native α-conotoxins preferably adopt the globular connectivity, and previous studies of α-
conotoxins have focused on the globular isomers as the ribbon and bead isomers typically have lower 
potency at nAChRs than the globular form. A recent report showed that the bead and ribbon isomers of 
GeXIVA are more potent than the globular isomer, with low nanomolar half-maximal inhibitory 
concentrations (IC50). Despite this high potency, the therapeutic potential of GeXIVA is limited, because 
like most peptides, it is susceptible to proteo-lytic degradation and is challenging to synthesize in high 
yield. Here we used backbone cyclization as a strategy to improve the folding yield as well as increase the 
serum stability of ribbon GeXIVA while preserving activity at the α9α10 nAChR. Specifically, cyclization of 
ribbon GeXIVA with a two-residue linker maintained the biological activity at the human α9α10 nAChR and 
improved stability in human serum. Short linkers led to selective formation of the ribbon disulfide isomer 
without requiring orthogonal protection. Overall, this study highlights the value of backbone cyclization in 
directing folding, improving yields, and stabilizing conotoxins with therapeutic potential. 
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Conotoxin GeXIVA inhibits the 910 nicotinic acetylcho-
line receptor (nAChR) and is analgesic in animal models of pain.
-Conotoxins have four cysteines that can have three possible
disulfide connectivities: globular (CysI–CysIII and CysII–CysIV),
ribbon (CysI–CysIV and CysII–CysIII), or bead (CysI–CysII and
CysIII–CysIV). Native -conotoxins preferably adopt the globu-
lar connectivity, and previous studies of -conotoxins have
focused on the globular isomers as the ribbon and bead isomers
typically have lower potency at nAChRs than the globular form.
A recent report showed that the bead and ribbon isomers
of GeXIVA are more potent than the globular isomer, with
low nanomolar half-maximal inhibitory concentrations (IC50).
Despite this high potency, the therapeutic potential of GeXIVA
is limited, because like most peptides, it is susceptible to proteo-
lytic degradation and is challenging to synthesize in high yield.
Here we used backbone cyclization as a strategy to improve the
folding yield as well as increase the serum stability of ribbon
GeXIVA while preserving activity at the 910 nAChR. Specif-
ically, cyclization of ribbon GeXIVA with a two-residue linker
maintained the biological activity at the human 910 nAChR
and improved stability in human serum. Short linkers led to
selective formation of the ribbon disulfide isomer without
requiring orthogonal protection. Overall, this study highlights
the value of backbone cyclization in directing folding, improv-
ing yields, and stabilizing conotoxins with therapeutic potential.
Acetylcholine receptors are present in the nervous system
and at neuromuscular junctions and are defined as either
muscarinic acetylcholine receptors or nicotinic acetylcho-
line receptors (nAChRs)2 (1, 2). Neuronal nAChR subtypes
are homo- or heteropentamers formed by the combination of
 (2–10) and  (2–4) subunits. These neuronal nAChR
subtypes are involved in a range of conditions and diseases,
including neuropathic pain, nicotine addiction, schizophrenia,
Parkinson’s disease, and Alzheimer’s disease (3, 4).
Conotoxins are disulfide-rich peptides found in the venoms
of marine cone snails that can selectively and potently alter the
function of ion channels and receptors of the nervous system
(5–7). Some have been used as pharmacological probes or
developed as drug leads (8, 9). One notable example is -cono-
toxin MVIIA (also called ziconotide or Prialt), which targets
the calcium channel CaV2.2 and is an approved drug to treat
neuropathic pain (10, 11). Likewise, Vc1.1 reached phase II clin-
ical trials for the treatment of neuropathic pain, and RgIA also
entered phase I trials. These latter two peptides have high
potency at the 910 nAChR, which is considered a pain target,
although the full mechanism(s) of analgesia are not understood
(12, 13), and G protein-coupled receptors such as the GABAB
receptor have also been suggested as targets (14 –17).
The sequence of conotoxin GeXIVA was identified recently
in a transcriptome analysis of the venom duct of Conus genera-
lis (18). This 28-amino acid peptide has four cysteines (Cys
I–IV) that can theoretically form three isomers depending on
the disulfide connections: globular (CysI–CysIII and CysII–
CysIV), ribbon (CysI–CysIV and CysII–CysIII), or bead (CysI–
CysII and CysIII–CysIV) as shown in Fig. 1. Surprisingly, all three
isomers of GeXIVA inhibit the rat 910 nAChR with similar
potency, although the bead and ribbon isomers are slightly
more potent than the globular (IC50 of the bead  4.6 nM; rib-
bon  7.0 nM; and globular  22.7 nM) (18). NMR structure
calculations have shown that ribbon GeXIVA is flexible while
still having a more defined structure than the other two isomers
(18). These isomers exhibit higher or similar potency at rat
910 nAChR compared with Vc1.1 (19) or RgIA (20). In addi-
tion, the ribbon and bead isomers of GeXIVA showed promise
in relieving neuropathic pain in a chronic constriction injury
model and also in a tail-flick model of acute pain (21).
Peptides, including conotoxins, typically have low oral bio-
availability and are easily degraded by proteases in vivo, thus
decreasing their therapeutic potential (22–24). Over the last
decade, cyclic peptides have been discovered in animals, plants,
fungi, and bacteria and offer clues toward improving the stabil-
ity of peptides (25–27). Head-to-tail cyclic peptides are typi-
cally more resistant to thermal or enzymatic degradation than
their linear counterparts (28, 29). Improving the stability of
conotoxins in biological fluids using backbone cyclization was
initially inspired by research into naturally occurring cyclic
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peptides (29, 30) and is a proven strategy to improve the stabil-
ity of peptides, including conotoxins (31). For example, the sta-
bility of -conotoxins MII, ImI, Vc1.1, RgIA, AuIB, and -cono-
toxin MrIA was significantly improved through backbone
cyclization, and most of the cyclic peptides had similar or
improved activity compared with their parent peptides (32).
Most notably, Vc1.1 became orally active in animal models of
pain after backbone cyclization (33). The length and amino acid
composition of the linker used to join the N and C termini of the
parent peptide are vital factors for backbone cyclization. For
example, the length of the linker has been shown to modulate
the yields of the three isomers of framework I conotoxins (cor-
responding to a CC-C-C pattern) and influence their biological
activities (34 –38).
Here we investigated whether a similar strategy could be
used for -conotoxin GeXIVA. We used backbone cyclization
to control the selective formation of the ribbon isomer and
investigated the effects of cyclization on structure, activity, and
stability. The ribbon isomer is formed by the oxidation of two
cysteine residues located near the N and C termini of the pep-
tide, suggesting that backbone cyclization could be used to
direct the selective formation of the resultant disulfide bond.
The three isomers of linear GeXIVA and a suite of cyclic ribbon
GeXIVA analogs were synthesized, and their serum stabilities
and biological activities at the human 910 (h910) nAChR
were tested.
Results
Cyclic GeXIVA ribbon isomer retains native structure
NMR structure calculations for ribbon GeXIVA (18) showed
that its N and C termini are maintained in close proximity
(6.4 Å) by a disulfide bridge between the first and last Cys
residues (Fig. 1). Five linkers were designed using molecular
modeling to bridge the termini, and all were geometrically
compatible with the linear peptide structure, with the cyclic
backbones maintained within 1 Å root-mean-square deviation
(RMSD) of the linear peptide. The data suggested that even a
one-residue linker is sufficient to cyclize the backbone of rib-
bon GeXIVA without perturbing structure. Models of cyclic
GeXIVA with minimum perturbation of the parent peptide
backbone are shown in Fig. 2. For experimental validation, we
focused on three short linkers (G, GG, and GAG) and the three
corresponding cyclic variants: ribbon cGeXIVA_G, ribbon
cGeXIVA_GG, and ribbon cGeXIVA_GAG. The three isomers
of linear GeXIVA and the three cyclic ribbon analogs were syn-
thesized using orthogonal protection of the cysteine side chains
to orient the folding toward a unique disulfide isomer. The
yields of three isomers of linear GeXIVA and cyclic ribbon
GeXIVA were low (1%) using a two-step oxidation method.
Although we optimized the purification procedure, globular
GeXIVA could not be completely purified. We therefore ex-
plored an alternative one-pot synthetic approach.
One-pot oxidative folding
Non-directed oxidative folding of GeXIVA and cGeXIVA_
GG was carried out in NH4HCO3 (pH 8.3) at room temperature
(Fig. 3A). For GeXIVA, three major products were formed
within 20 h. The three major peaks were observed in the ultra-
performance liquid chromatography trace, accounting for 25,
45, and 30% of the total peptide, respectively. Analysis of each
peak using a TripleTOF 5600 mass spectrometer (AB SCIEX,
Concord, Canada) with a nanoelectrospray ionization source
revealed masses of 3450.62, 3450.62, and 3450.63 Da, respec-
tively, each corresponding to fully oxidized GeXIVA. The three
peaks were unambiguously identified by co-elution with the
globular GeXIVA, bead GeXIVA, and ribbon GeXIVA isomers.
The HPLC peaks of ribbon and bead GeXIVA partly overlapped
and were difficult to separate (Fig. 3A, 24h). Interestingly, a
single peak representing the majority of the oxidized forms
transiently appeared from 1 to 4 h and then disappeared from 4
to 8 h (Fig. 3A, black asterisk). This transient peak partly over-
laps with the major final product (Fig. 3A, 24h), which was
identified as globular GeXIVA. We hypothesized that the
globular isomer might form within 4 h and then gradually con-
vert into other isomers. We incubated globular GeXIVA in
NH4HCO3 (pH 8.3) at room temperature at a final concentra-
tion of 20 M and the globular GeXIVA was found to be very
stable in the folding buffer for 24 h (data not shown), suggesting
that the first major peak at 4 h mainly comprises intermediate
forms with similar retention time to the globular isomer.
The one-step oxidation of reduced cGeXIVA_GG was com-
plete at 16 h, whereas some intermediates could still be seen at
Figure 1. The three isomers of -conotoxin GeXIVA and the 3D NMR solution structure of ribbon GeXIVA (18). Cys residues are labeled with Roman
numerals (I–IV), and the disulfide bonds are shown as yellow sticks. The structure shown for the ribbon GeXIVA is the lowest energy conformer from an ensemble
of 10 NMR models.
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that time for the linear GeXIVA. Only three products were
formed, all of mass 3546.66 Da, corresponding to that of the
fully oxidized cGeXIVA_GG. The third major peak accounted
for 86% of the total peptide content and was confirmed as being
the ribbon isomer by co-elution. The two other peaks are pre-
sumably the globular and bead isomers. In contrast to linear
GeXIVA, the retention time of globular, bead, and ribbon iso-
mers of cGeXIVA_GG separate well (Fig. 3A) as the linker
engenders ribbon cGeXIVA_GG with a larger hydrophobic
patch than ribbon GeXIVA (Fig. 3B, green), which could explain
its later retention time. Four intermediate forms were identified
over the time course. The major intermediate (Fig. 3A,
blue asterisk and labeled I1) was the most abundant of the
oxidized forms from 1 to 4 h. The major intermediate I1 of
cGeXIVA_GG was isolated, and its mass was 3548.66 Da, indi-
cating that it has only one disulfide bond. The masses of the
three minor intermediates were each 3546.65 Da, suggesting
that they have two disulfide bonds (all labeled I2 in Fig. 3A).
NMR analyses of ribbon GeXIVA and ribbon cGeXIVA_GG
A comparison of the secondary H chemical shifts of ribbon
GeXIVA with those of ribbon cGeXIVA_GG suggested very
little difference in structure between the linear and cyclic ana-
logs (Fig. 4A). The different chemical environment created by
the presence of the cyclizing linker can easily explain the min-
imal shift differences near the termini. Overlapping peaks in the
2D NMR spectra prevented the unambiguous assignment of
the cGeXIVA_G and cGeXIVA_GAG spin systems.
The 3D structure of cGeXIVA_GG was calculated with a
total of 171 distance restraints and found to contain a short
310-helix (from Pro12 to Arg16; Fig. 4B). The Ser11–Pro12 pep-
tide bond was determined to adopt a trans configuration, sim-
ilar to the configuration of this bond in the ribbon and bead
isomers of linear GeXIVA (18). As shown for ribbon GeXIVA
(18), the loop formed between Cys9 and Cys20 overlays reason-
ably well between NMR models (RMSD of 1.38  0.56 Å across
backbone atoms of residues 9 –20; Table 1), although the
remainder of the peptide is somewhat disordered, suggesting a
degree of flexibility. We thus used NMR spin relaxation
measurements to characterize the backbone dynamics of
cGeXIVA_GG (Fig. 5 and Table 2). Heteronuclear T1 and
NOEs were measured and used to derive order parameters
reflective of motion of the C-H bonds. Because of spectral
overlap, only 18 of the 30 residues could be analyzed. Neverthe-
less, the order parameters (0.53–0.81; mean of 0.63) suggest that
cGeXIVA_GG is moderately flexible, which agrees with the
geometric analysis of the lowest energy structures. The least
flexible region is at the C-terminal end of the Cys9 to Cys20 loop.
Ribbon cGeXIVA_GG and ribbon GeXIVA are equipotent
inhibitors of the human 910 nAChR subtype
Linear GeXIVA isomers have been shown to selectively and
potently inhibit the rat 910 nAChR subtype (18). Here, glob-
ular, bead, and ribbon isomers of linear GeXIVA, and cyclic
constructs of ribbon GeXIVA (cGeXIVA_G, cGeXIVA_GG,
and ribbon cGeXIVA_GAG) were tested for their functional
activity at the h910 nAChR subtype heterologously ex-
pressed in Xenopus laevis oocytes. All three cyclic ribbon con-
structs tested at 100 nM inhibited ACh-evoked currents medi-
ated by h910 nAChRs by 60 –70% (n  4 – 6). Similarly,
Figure 2. Amino acid sequences and NMR structure of ribbon GeXIVA and cyclic ribbon isomers of GeXIVA. A, amino acid sequences of ribbon GeXIVA
and cyclic analogs. The backbone cyclization of ribbon GeXIVA was carried out using different sized linkers (highlighted in red) spanning its N and C termini
(indicated by the black bracket and line). The black curved lines below the sequence show the ribbon disulfide connectivity. The -carbon (C) RMSD of the
backbone for the parent peptide and molecular models of the cyclic peptides are shown in the last column. B, NMR solution structure of ribbon GeXIVA (green)
and models of cyclic variants (backbones in blue and linkers in red). The disulfide bonds are represented by yellow sticks, and the C are shown as balls.
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the bead (n  5) and ribbon isomers (n  8) of GeXIVA
inhibited the h910 ACh-evoked current amplitude by
60 –70%. In contrast, the globular GeXIVA was less potent,
inhibiting h910 ACh-evoked currents by 40% (n  12)
(Fig. 6A).
The concentration-dependent activity of globular and rib-
bon GeXIVA, and ribbon cGeXIVA_GG at h910 nAChRs
were determined (Fig. 6B). All peptides reversibly inhibited
ACh-evoked currents in a concentration-dependent manner,
giving IC50 values of 198.6  18.9 nM (n  4 –12) for globular
GeXIVA, 35.1  2.7 nM (n  4 – 8) for ribbon GeXIVA and
37.6  4.9 nM (n  4 –11) for ribbon cGeXIVA_GG. Consistent
with the previously reported potency of globular and ribbon
GeXIVA at rat 910 nAChRs, the globular isomer of GeXIVA
Figure 3. Time course of the oxidative folding of GeXIVA and cGeXIVA_GG. A, HPLC traces of samples taken at various times during the random folding
process. For GeXIVA, the black asterisk indicates that the peak occurring in the folding process of GeXIVA comprises intermediate forms with similar retention
time to the globular isomer, and the red asterisk indicates an impurity. The globular, bead, and ribbon GeXIVA from two-step oxidations are shown as red, green,
and blue traces, respectively. For cGeXIVA_GG, the blue asterisk indicates the major intermediate occurring in the folding process of cGeXIVA_GG. The ribbon
cGeXIVA_GG from two-step oxidation is shown as a blue trace. I1 represents the intermediate with one disulfide bond, and I2 represents the intermediates with
two disulfide bonds. B, surface representations of ribbon GeXIVA and ribbon cGeXIVA_GG. Positively charged residues are shown in blue, negative residues are
red, polar residues are white, and hydrophobic residues are green. Surface representations were created using the program PyMOL. Cyclization of ribbon
GeXIVA resulted in an additional hydrophobic patch (circle) in cGeXIVA_GG.
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had lower potency at h910 nAChRs than the ribbon analog.
Ribbon GeXIVA and ribbon cGeXIVA_GG had similar IC50
values, suggesting that backbone cyclization had no impact on
the potency of inhibition at h910 nAChRs.
Serum stability of linear GeXIVA and ribbon cGeXIVA isomers
Stability assays for the ribbon isomer of GeXIVA and its three
cyclic analogs were carried out in human serum. All four pep-
tides degraded within 2 h, but the ribbon cGeXIVA_GG
was slightly more stable than the other peptides (data for
cGeXIVA_G and GeXIVA_GAG not shown). Subsequently,
the stability of the three isomers of linear GeXIVA and of rib-
bon cGeXIVA_GG was compared with that of -conotoxin
cVc1.1 (33) in 25% human serum. The positive control, cVc1.1,
was highly stable, whereas only 20% of the three isomers of
GeXIVA remained after 4 h of incubation. Ribbon cGeXIVA_
GG was more stable than the three linear isomers of GeXIVA
(p  0.001) at the 4-h time point, with 38% of cGeXIVA_GG
remaining (Fig. 7).
Discussion
The 910 nAChR mediates efferent olivocochlear innerva-
tions in outer hair cells and modulates immune responses in
lymphocytes (39 – 41). It is also reported to be implicated in
pain and cancer (42, 43). Only a handful of -conotoxins is
currently known to selectively inhibit the 910 nAChR (18,
44 – 46), so studies of new examples such as GeXIVA are impor-
tant for defining receptor specificity. Furthermore, previous
studies have highlighted the value of backbone cyclization to
enhance the biopharmaceutical properties of -conotoxins
(33, 47), and so here we attempted to apply this approach to
GeXIVA.
Molecular modeling was used to design linkers comprising
only a small number of amino acids that would introduce min-
imal constraints into the peptide fold. A recent study high-
lighted the importance of the distance between the N and C
termini in designing cyclizing linkers (48), but considering dis-
tances alone will not address limitations caused by accessible
conformations of backbones nor the orientation of the termini.
Structural perturbations may be introduced unintentionally
into a cyclic peptide when a linker is designed on the basis of
distance only, ultimately decreasing biological activity (47, 49).
In the case of ribbon GeXIVA, modeling showed that the prox-
imity of the termini would allow cyclization with a single resi-
due linker without affecting the structure. Because non-neutral
amino acids in the cyclizing linker sequence can have a negative
effect on biological activity (50), only Gly and Ala amino acids
were used in the linkers in the current study. These residues are
small, flexible, non-charged, and likely to have minimal inter-
ference with biological activity. No more than two sequential
Gly or Ala were used in any individual linker to avoid overlap-
ping peaks in NMR spectra and thus avoid spectral assignment
Figure 4. Structural characterization of cGeXIVA_GG. A, secondary H chemical shifts of ribbon GeXIVA and ribbon cGeXIVA_GG (H). The overall
secondary structures of ribbon GeXIVA and ribbon cGeXIVA_GG are similar, and both peptides display a 310-helix from Pro
12 to Arg16. The black lines below the
sequence show the ribbon disulfide connectivity. B, ribbon diagram of the NMR solution structure of cGeXIVA_GG. Models were overlaid over the Cys9–Cys20
segment. Disulfide bonds are shown in yellow.
Table 1
Statistical analysis of cGeXIVA_GG structures
All statistics are given as means  S.D.
Experimental restraints
Total no. distance restraints 171
Intraresidue 90
Sequential 73
Medium range, i  j  5 8
Long range, i  j  5 0
Hydrogen bond restraints 2
Dihedral angle restraints 32
NOE violations exceeding 0.3 Å 0
Dihedral violations exceeding 2.0 Å 0
RMSD from mean structure, Å
Backbone atoms (residues 9–20) 1.38  0.56
All heavy atoms (residues 9–20) 3.33  0.98
Stereochemical qualitya
Residues in most favored Ramachandran region, % 77.9  8.9
Ramachandran outliers, % 1.4  1.8
Unfavorable side-chain rotamers, % 3.7  2.6
Clashscore, all atoms 0.1  0.4
Overall MolProbity score 1.6  0.3
a According to MolProbity (76).
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difficulties. Linkers composed of Gly and Ala residues have
been successfully used to cyclize the -conotoxins MII, RgIA,
and Vc1.1, without adversely affecting biological activity or
structure (33, 47, 49).
The linkers used in this study did not affect the activity and
structure of ribbon GeXIVA. Indeed, all cyclic ribbon variants,
i.e. cGeXIVA_G, cGeXIVA_GG, and cGeXIVA_GAG, had sim-
ilar activity to the linear ribbon form at the h910 nAChR.
Although no structural data from peptides cyclized with a G or
GAG linker were obtained because of NMR spectral overlap,
the GG linker did yield a cyclized peptide with a very similar
conformation to the linear ribbon GeXIVA. Alignment of the
lowest energy model generated from NMR data and an analysis
of the backbone relaxation measurements suggests that the
cyclic variant is most rigid in the Cys9–Cys20 loop region but
slightly more flexible in the remainder of the molecule. It has
recently been shown that backbone cyclization can enhance or
retain backbone rigidity for three different classes of peptides,
including for the conotoxin Vc1.1 (51). Cyclization appears to
have less of a rigidifying effect in GeXIVA.
The non-directed oxidation of GeXIVA resulted in the pref-
erential formation of the bead isomer, followed by the ribbon
and globular forms, which interestingly parallels their biologi-
cal activity (18). By contrast, two previous studies employing
the one-step oxidation of -conotoxins showed preferential
Figure 5. Experimental relaxation data and derived order parameters for
cGeXIVA_GG. T1 (top panel) and heteronuclear NOE (middle panel) values for
the C nuclei were measured at 600 MHz. Errors are shown as standard devi-
ations of triplicate measurements. Only 18 of the residues could be analyzed.
A model-free analysis was used to derive order parameters (bottom panel).
Models 1 and 2 of model-free were used in the analysis. Errors, shown as
standard deviation, were estimated using a Monte Carlo algorithm.
Table 2
Relaxation data, fitted parameters, and error estimates for cGeXIVA_
GG
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formation of the globular isomer under similar conditions (0.1 M
NH4HCO3, pH 8, room temperature) (52, 53). A possible
explanation for this difference in isomer formation is that
GeXIVA displays a Cys framework XIV (C-C-C-C) with 6, 10,
and 6 residues within the CysI–CysII, CysII–CysIII, and CysIII–
CysIV backbone segments, respectively, rather than the Cys
framework I (CC-C-C) of most -conotoxins with 0, 4, and 3–7
residues between the cysteines.
The one-step oxidation of cGeXIVA_GG was notably differ-
ent from that of the linear parent peptide because it resulted in
the preferential formation of the ribbon isomer. The use of
short cyclizing linkers has also been reported to drive oxidative
folding toward the ribbon connectivity for three other conotox-
ins: -conotoxins ImI and AuIB and -conotoxin MrIA. Like
GeXIVA, these peptides have four Cys residues, with CysI and
CysIV being no more than three residues from the N and C
termini, respectively. A short cyclizing linker should maintain
these two Cys residues in spatial proximity in the reduced
form and favor their cross-linking by a disulfide bond during
oxidation.
During the oxidative folding of ribbon GeXIVA and rib-
bon cGeXIVA_GG, a major intermediate was identified. For
GeXIVA, the amount of ribbon and globular isomers plateaued
after 8 and 12 h of incubation, respectively, whereas the bead
form plateaued after 20 h. According to Wedemeyer et al. (54),
the rate of formation of disulfide bonds in an unstructured
chain decreases with the number of residues between the
two cysteines. Because 6, 10, and 6 residues exist between
successive cysteines in GeXIVA, we speculate that the major
intermediate might involve a disulfide bond between CysI
and CysII or between CysIII and CysIV and that this interme-
diate subsequently translates into the bead isomer. For
cGeXIVA_GG, there are only four residues between CysI and
CysIV after backbone cyclization, which may favor the for-
mation of either a CysI–CysIV or CysII–CysIII disulfide bond
in the intermediate, thus leading to the ribbon isomer. Inter-
estingly, three intermediates with two disulfide connectivi-
ties appeared during the course of folding of cGeXIVA_GG.
The retention times of these three intermediates were differ-
ent from the three stable isomers, suggesting that the inter-
mediates have native-like connectivities but have meta-sta-
ble conformations.
We hypothesize that the preferential formation of the ribbon
isomer probably results from the destabilization of the alterna-
tive connectivities rather than through stabilization of the rib-
bon form (Fig. 8). Backbone cyclization of ribbon GeXIVA pos-
sibly affects the folding energy through an entropic effect,
mainly impacting the unfolded state. Indeed, the linker has little
interaction with the rest of the peptide in molecular models,
suggesting that the termini are already maintained in proximity
in the linear form, and cyclization does not result in structural
perturbation to the core of the peptide. By contrast, the bead and
globular isomers probably adopt a different set of conformations
after being backbone cyclized because NMR characterization of
these isomers indicates that the globular form is disordered, and
the N and C termini of the bead isomer are uncoupled (18).
A two-step oxidation strategy is often used to oxidize cono-
toxins containing two disulfide bonds because the yields are
Figure 6. Inhibition of human 910 nAChR by linear GeXIVA and ribbon cGeXIVA isomers. A, bar graph of globular GeXIVA, bead GeXIVA, ribbon
GeXIVA, ribbon cGeXIVA_G, ribbon cGeXIVA_GG, and ribbon cGeXIVA_GAG (100 nM) inhibition of ACh-evoked peak current amplitude mediated by h910
nAChRs. Whole-cell h910 nAChR-mediated currents were activated by 6 M ACh. B, concentration–response curves of globular and ribbon GeXIVA and
ribbon cGeXIVA_GG inhibition of ACh-evoked currents mediated by h910 nAChRs (means  S.E., n  4 –12).
Figure 7. The stability of GeXIVA isomers, ribbon cGeXIVA_GG, and cVc1.1
(positive control) in 25% human serum. The one-way analysis of variance/
Tukey test and was used for comparing the remaining peptides at the 4-h
time point, and the data are expressed as the means  S.E. ***, p  0.001. All
values (except cVc1.1) were compared with that of ribbon GeXIVA.
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typically improved compared with undirected folding (55).
However, the oxidation of GeXIVA using this strategy only pro-
duced small amounts of products, hindering high-throughput
structure-activity relationship studies and therapeutic studies.
The yield of folded ribbon GeXIVA calculated from the final
weight of oxidized peptide divided by the weight of reduced
peptide was 0.5%. Using the results of Cheneval et al. (56) to
extrapolate the yield for synthesis of an unprotected peptide,
the yield of cyclic ribbon cGeXIVA_GG through a one-step
folding method should be 8.6% using Fmoc-based solid-
phase peptide synthesis and considerably higher for a Boc-
based approach. Additionally, the HPLC elution peaks of rib-
bon and bead isomers of GeXIVA overlapped, whereas
the ribbon isomer of cGeXIVA_GG is distinct, and ribbon
cGeXIVA_GG therefore can be produced in greater purity
using one-step oxidation than the ribbon GeXIVA using the
same strategy.
An alternative strategy to increase the oxidative folding yield
has been used in other cases of disulfide-rich peptides, includ-
ing the widely used model system bovine pancreatic trypsin
inhibitor (BPTI). Undirected folding of this protein results in
the formation of two main species, one being native BPTI and
the other a native-like two-disulfide intermediate (57). The
addition of the N-terminal pro-region increased substantially
the native BPTI formation, and it was identified that a cysteine
residue in this region was responsible for this increased yield
(58). Tethering a cysteine residue to the C terminus with a flex-
ible linker resulted in a similar effect, indicating that this resi-
due acts as an internal catalyst.
Backbone cyclization typically improves the stability of dis-
ulfide-rich peptides against enzymatic degradation, as demon-
strated for several conotoxins, chlorotoxin, and a spider toxin
(32, 35–38, 59, 60). However, it was recently reported that cycli-
zation of 	-conotoxin PVIIA decreased its stability in human
serum (61), without significantly perturbing the structure rela-
tive to the native form (62). Here, we show that the IC50 for
cGeXIVA_GG inhibition of h910 nAChR (37.7  5.0 nM) is
comparable with that for ribbon GeXIVA (35.1  2.7 nM). The
stability in human serum of ribbon cGeXIVA_GG is only
slightly improved compared with linear GeXIVA, suggesting
that the main routes of degradation of GeXIVA are by endopro-
teases or side chain denaturation, which are typically less
affected by backbone cyclization. A possible target for such
endoproteases are the nine arginine residues in the sequence of
GeXIVA (63).
Using short linkers to enhance oxidative folding and other
biopharmaceutical properties of bioactive peptides has broader
applications than just for toxins, with perhaps a most striking
example being for insulin. Insulin is an extremely important
hormone but is difficult to synthesize because of its two chain
unique structure (64). In one study, the two peptide chains of
human insulin were fused, increasing the production yield
compared with native human proinsulin (65) while maintaining
a native-like structure (66) but with an attendant loss of biolog-
ical activity (67). In a later study, Hua et al. (68) used a six-
residue linker, and the resulting insulin variant maintained bio-
logical activity and structure and also had improved folding
yield and stability. More recently, the nature of the linker region
between the two insulin chains was further investigated, result-
ing in the identification of an insulin variant with the highest
folding efficiency to date (64). In that study, it was shown that
the linker region had a direct effect on folding yield by enhanc-
ing the formation of the native disulfide bond connectivity. The
peptides in the current study have a direct analogy to single-
chain insulin analogs: a suitable linker for cGeXIVA_GG led to
preferential formation of the ribbon isomer and significantly
improved the product yield and stability while retaining the
native-like structure and biological activity. The enhanced
pharmaceutical properties deriving from a suitable linker pro-
vide an opportunity to develop GeXIVA as a potential thera-
peutic for the treatment of neuropathic pain, a condition with a
huge unmet medical need (69). Treatment of neuropathic pain
is challenging, and alternative therapeutics are needed because
currently available drugs such as morphine, gabapentin, or
antidepressants are subject either to the development of toler-
ance or to significant side effects (70, 71).
In summary, the head-to-tail backbone cyclization via a short
linker of ribbon GeXIVA had no impact on the potency of
inhibition at h910 nAChR and a rationally designed linker
favored the formation of the ribbon disulfide connectivity and
improved stability in human serum. The high-yield production
of ribbon cGeXIVA_GG compared with linear GeXIVA should




Linkers were designed using molecular modeling. The struc-
ture of the ribbon isomer cyclized with linkers from one to five
amino acid residues was modeled. Fifty models of the backbone
cyclized ribbon GeXIVA were generated for each of the linkers
using Modeler 6v13 (72), and the conservation of ribbon
GeXIVA native conformation was measured by computing the
Figure 8. Schematic representation of the relative energy of the three
linear isomers of GeXIVA (black lines) and their cGeXIVA_GG (dotted red
lines) analogs. The energy difference between isomers of the same peptide
was computed using a Boltzmann distribution of the isomers at equilibrium.
Cyclization improves selective folding of conotoxin GeXIVA

















mean C root-mean-square deviation between the models and
the 20 lowest-energy NMR structures (18).
Peptide synthesis, cyclization, oxidation, and purification of
GeXIVA and variants
The three isomers of GeXIVA and the three cyclic analogs
(cGeXIVA_G, cGeXIVA_GG and cGeXIVA_GAG) were syn-
thesized using Fmoc-based solid-phase peptide synthesis on an
acid-sensitive resin 2-chlorotrityl chloride. Side chains of Cys
residues were protected in pairs with orthogonal protective
groups that can be removed selectively under different oxida-
tion conditions. The acid-labile trityl group was used to protect
the side chains of Cys2 and Cys27, and the acetamidomethyl
group was used to protect Cys9 and Cys20 for the ribbon
GeXIVA and its cyclic variants. The backbone cyclization of
cyclic variants was achieved using the protocol described
recently (56). Briefly, a solution of 1% TFA in dichloromethane
(v/v) was used to cleave the linear precursor peptides of the
cyclic variants off the resin. The side chain protected precursor
peptides were dried, cyclized in O-(7-azabenzotriazol-1-yl)-
N,N,N,N-tetramethyluronium hexafluorophosphate (5 mM)
and N,N-diisopropylethylamine (10 mM) in N,N-dimethylfor-
mamide for 3 h and lyophilized. The protecting group on side
chains was removed in TFA with 2% triisopropylsilane and 2%
water (v/v) for 2 h. The three isomers of GeXIVA were cleaved
and deprotected in TFA with 2% triisopropylsilane and 2%
water (v/v) for 2 h.
Two-step oxidative folding was used to form disulfide bonds:
the first disulfide bond was formed in 0.1 M ammonium bicar-
bonate (NH4HCO3, pH 8.3) at room temperature (21–24 °C)
for 24 h, and the second disulfide bond was formed in 0.1 M
iodine solution for 1 h. All peptides were purified by reversed-
phase (RP)-HPLC using Phenomenex C18 columns, and the
purification method is 15–25% buffer B within 40 min (increas-
ing 1% buffer B per 4 min). Buffer A is 0.05% TFA in water, and
buffer B is 0.045% TFA in 90% acetonitrile.
NMR spectroscopy
Samples of ribbon GeXIVA and its cyclic analogs were pre-
pared by dissolving peptide (1 mg) in 90% H2O, 10% D2O at a
pH of 3. The spectra were recorded on a Bruker Avance III
600 MHz NMR spectrometer at 298 K and included total cor-
relation spectroscopy (mixing time of 80 ms), NOESY (mix-
ing time of 200 ms), and H-N and H-C heteronuclear single
quantum coherence. Chemical shifts were referenced to
internal 2, 2-dimethyl-2-silapentane-5-sulfonate at 0 ppm.
The spectra were processed with Topspin (Bruker Biospin)
and analyzed with CcpNMR analysis (version 2.4.1). Second-
ary H chemical shifts were calculated as the difference
between the observed H chemical shifts and that of the
corresponding residues in a random coil peptide (73). Struc-
ture calculations were based upon distance restraints as
derived from NOESY spectra and on backbone 
 and  dihe-
dral angle restraints generated using TALOS	 (74). A family
of structures consistent with the experimental restraints was
calculated using CYANA (75).
Relaxation measurements
NMR relaxation measurements were carried out as described
previously (51). Briefly, 13C T1 (spin-lattice) relaxation times
were measured using the Bruker pulse program hsqct1etgpsi3d.2.
Spectra were acquired with a spectral width of 10 ppm over
2048 complex points in the 1H dimension and 22 ppm over
60 complex points in the 13C dimension. To determine T1
values, nine relaxation delays in the range of 0.01–1.0 s were
used. A recycle delay of 3 s was used. 13C NOEs were mea-
sured using the pulse program hsqcnoegpsi.2. Peak volumes
were measured in CCPNMR. A recycle delay of 5 s was used.
All experiments were carried out in triplicate. Order param-
eters were calculated by a model-free analysis using the same
protocol and target function as described previously (51),
but here the goodness-of-fit for the NOE values were given a
25% weighting compared with the T1 values to allow for the
higher uncertainty in the experimental NOE measurements.
Folding assays
Ribbon GeXIVA and cGeXIVA_GG were reduced with 10
mM dithiothreitol and isolated using RP-HPLC. Reduced pep-
tides were dissolved in 0.1 M NH4HCO3 buffer (pH 8.3) at 20 M
and stirred at room temperature. An aliquot of peptide solution
was removed after 0, 1, 4, 8, 12, 16, 20, and 24 h and quenched
with 2% TFA. All samples were analyzed with ultra-perfor-
mance liquid chromatography using a gradient 11–18% buffer
B within 28 min (increasing 1% buffer B per 4 min) in an ana-
lytical Vydac C18 column.
In vitro cRNA synthesis
Plasmid pT7TS constructs of human 9 and 10 nAChR
subunits were linearized with XbaI restriction enzymes (New
England Biolabs, Ipswich, MA) for in vitro cRNA transcription
using T7 mMessage mMachine transcription kits (Ambion,
Foster City, CA).
Oocyte preparation and microinjection
Stage V–VI oocytes were obtained from X. laevis, defollicu-
lated with 1.5 mg/ml collagenase type II (Worthington Bio-
chemical Corp., Lakewood, NJ) at room temperature (21–
23 °C) for 1–2 h in OR-2 solution containing 82.5 mM NaCl, 2
mM KCl, 1 mM MgCl2, and 5 mM HEPES, pH 7.4. The oocytes
were injected with 35 ng of cRNA for h910 nAChR (concen-
tration confirmed spectrophotometrically and by gel electro-
phoresis) using glass pipettes pulled from glass capillaries
(3-000-203 GX; Drummond Scientific Co., Broomall, PA). The
oocytes were incubated at 18 °C in sterile ND96 solution com-
posed of 96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and
5 mM HEPES, pH 7.4, supplemented with 5% fetal bovine
serum, 50 mg/liter gentamicin (Gibco) and 10,000 units/ml
penicillin-streptomycin (Gibco).
Oocyte two-electrode voltage clamp recording and data
analysis
Electrophysiological recordings were carried out 2–5 days
after cRNA microinjection. The oocytes expressing h910
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nAChRs were incubated in 100 M BAPTA-AM 3 h before
recording. Two-electrode voltage clamp recordings were per-
formed at room temperature using a GeneClamp 500B ampli-
fier and pClamp9 software interface (Molecular Devices,
Sunnyvale, CA) at a holding potential 80 mV. Voltage-re-
cording and current-injecting electrodes were pulled from
GC150T-7.5 borosilicate glass (Harvard Apparatus, Holliston,
MA) and filled with 3 M KCl, giving resistances of 0.3–1 M
.
The oocytes were perfused with ND115 solution containing
115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl2, and 10 mM HEPES,
pH 7.4, using a continuous Legato 270 push/pull syringe pump
perfusion system (KD Scientific, Holliston, MA) at a rate of 2
ml/min.
Initially, the oocytes were briefly washed with ND115 solu-
tion followed by three applications of ACh at half-maximal
effective concentration (EC50) of 6 M ACh for h910 nAChR.
Washout with bath solution was done for 3 min between ACh
applications. The oocytes were incubated with peptides for 5
min with the perfusion system turned off, followed by co-appli-
cation of ACh and peptide with flowing bath solution. All pep-
tide solutions were prepared in ND115 	 0.1% bovine serum
albumin. Peak current amplitudes before (ACh alone) and after
(ACh 	 peptide) peptide incubation were measured using
Clampfit 10.7 software (Molecular Devices), where the ratio
of ACh 	 peptide-evoked current amplitude to ACh alone-
evoked current amplitude was used to assess the activity of the
peptides at human nAChRs.
All electrophysiological data were pooled (n  4 to 12) and
represent the means  S.E. Concentration–response curves
were obtained using GraphPad Prism 7 nonlinear regression
analysis (GraphPad Software, La Jolla, CA). The half-maximal
inhibitory concentration (IC50) was determined from the
concentration–response curve and reported with error of
the fit.
Stability assays
Serum stability of peptides were carried out in 25% human
serum (human male AB plasma; Sigma-Aldrich) over 4 h using
a 20 M final peptide concentration. Serum was prepared by
centrifugation at 17,000  g for 15 min to remove the lipid
component, and the supernatant was diluted 1 in 4 in phos-
phate-buffered saline and incubated at 37 °C for 15 min before
the assay. Each peptide was incubated in 25% human serum at
37 °C, and aliquots were taken out at time points 0, 1, 2, 3, and
4 h, respectively. Serum proteins were denatured with 2 M urea
and precipitated with 20% TFA. All samples were centrifuged at
17,000  g for 10 min, and the supernatant was analyzed by
analytical RP-HPLC. Remaining peptides were quantified using
peak height with absorption at 214 nm.
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